Skip to main content

Advertisement

SpringerLink
Log in

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The goal of this project was to investigate the contentious issue of a possible effect of endocrine therapy (ET) on sexual dysfunction (SD) in postmenopausal early stage breast cancer survivors. To date, few studies have assessed sexual functioning prior to initiating ET and none have taken sexual distress into account when reporting the prevalence of ET-induced SD. We report the findings of a study on the change in SD (defined as experiencing sexual problems causing distress) during the first 6 months of ET usage. Between January 2009 and May 2011, 118 patients entered the study and 66 completed questionnaires prior to initiation of ET and after 6 months of use. Sexual functioning (SF) was evaluated with the female sexual function index while sexual distress was assessed with the female sexual distress scale (FSDS-R). Gynecological symptoms were measured with the FACT-B ES subscale. Over time, the level of gynecological symptoms increased (p < 0.001), whereas no decline in SF was observed. The percentage of women who reported experiencing at least one sexual problem (85 %) and the percentage who were sexually distressed (30 %) remained the same across time. Importantly, the change in the prevalence of SD between baseline (24 %) and 6 months (29 %) was not statistically significant. Women experiencing SD at baseline were more likely to experience SD after 6 months of ET usage (OR = 7.4, 95 % CI = 1.5–36.9) than women who had no SD prior to initiating ET. The observation that SF remained stable across time is encouraging news. However, longer follow-up and the inclusion of women who were premenopausal at diagnosis are needed to determine the potential influence of extended duration of ET (e.g., at least 5 years) on SD. Further studies, including assessing the impact of early identification of patients at risk of developing SD and timely intervention, are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical Oncology (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796

    Article  PubMed  Google Scholar 

  2. National Comprehensive Cancer Network (2010) National Comprehensive Cancer Network: Clinical practice guidelines in breast cancer, version1 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  3. Fallowfield L (2011) Identification and management of treatment-related symptoms for breast cancer patients receiving adjuvant endocrine therapy. Eur J Cancer 47(Suppl 1):S80–S80

    Article  Google Scholar 

  4. Bradford A (2013) Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause 20(2):128–129

    PubMed  Google Scholar 

  5. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D’Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol 31(11):1398–1404

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Boehm DU, Lebrecht A, Eckhardt T, Albrich S, Schmidt M, Siggelkow W, Kandelhardt E, Koelbl H (2009) Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care (Engl) 18(5):500–506

    Article  Google Scholar 

  7. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Mok K, Juraskova I, Friedlander M (2008) The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. Breast 17(5):436–440

    Article  PubMed  Google Scholar 

  9. Dent SF, Gaspo R, Kissner M, Pritchard KI (2011) Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 126(2):295–310

    Article  CAS  PubMed  Google Scholar 

  10. Buijs C, de Vries EG, Mourits MJ, Willemse PH (2008) The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev 34(7):640–655

    Article  CAS  PubMed  Google Scholar 

  11. Chin SN, Trinkaus M, Simmons C, Flynn C, Dranitsaris G, Bolivar R, Clemons M (2009) Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 9(2):108–117

    Article  PubMed  Google Scholar 

  12. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97(5 Pt 2):855–866

    Article  CAS  PubMed  Google Scholar 

  13. Berglund G, Nystedt M, Bolund C, Sjödén PO, Rutquist LE (2001) Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 19(11):2788–2796

    CAS  PubMed  Google Scholar 

  14. Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ, Bloom JR (2006) Body image and sexual problems in young women with breast cancer. Psychooncology 15(7):579–594

    Article  PubMed  Google Scholar 

  15. Safarinejad MR, Shafiei N, Safarinejad S (2012) Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy. Psychooncology 22(6):1242–1248

    Article  PubMed  Google Scholar 

  16. Ochsenkühn R, Hermelink K, Clayton AH, von Schönfeldt V, Gallwas J, Ditsch N, Rogenhofer N, Kahlert S (2011) Menopausal status in breast cancer patients with past chemotherapy determines long-term hypoactive sexual desire disorder. J Sex Med 8(5):1486–1494

    Article  PubMed  Google Scholar 

  17. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J (2008) Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? J Sex Med 5(8):1898–1906

    Article  PubMed  Google Scholar 

  18. Biglia N, Moggio G, Peano E, Sgandurra P, Ponzone R, Nappi RE, Sismondi P (2010) Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 7(5):1891–1900

    Article  PubMed  Google Scholar 

  19. Gilbert E, Ussher JM, Perz J (2010) Sexuality after breast cancer: a review. Maturitas 66(4):397–407

    Article  PubMed  Google Scholar 

  20. Melisko ME, Goldman M, Rugo HS (2010) Amelioration of sexual adverse effects in the early breast cancer patient. J Cancer Surviv 4(3):247–255

    Article  PubMed Central  PubMed  Google Scholar 

  21. Speer JJ, Hillenberg B, Sugrue DP, Blacker C, Kresge CL, Decker VB, Zakalik D, Decker DA (2005) Study of sexual functioning determinants in breast cancer survivors. Breast J 11(6):440–447

    Article  PubMed  Google Scholar 

  22. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH (1999) Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17(5):1488–1492

    CAS  PubMed  Google Scholar 

  23. Mourits MJ, Böckermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH (2002) Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86(10):1546–1550

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Panjari M, Bell RJ, Davis SR (2011) Sexual function after breast cancer. J Sex Med 8(1):294–302

    Article  PubMed  Google Scholar 

  25. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20(2):162–168

    PubMed  Google Scholar 

  26. Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, Bower JE, Belin TR (2004) Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 96(5):376–387

    Article  PubMed  Google Scholar 

  27. Greendale GA, Petersen L, Zibecchi L, Ganz PA (2001) Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 8(2):111–119

    Article  CAS  PubMed  Google Scholar 

  28. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, Graziottin A, Heiman J, Laan E, Leiblum S, Padma-Nathan H, Rosen R, Segrayes K, Segrayes RT, Shabsigh R, Sipski M, Wagner G, Whipple B (2000) Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 163:888–893

    Article  CAS  PubMed  Google Scholar 

  29. Mimoun S, Wylie K (2009) Female sexual dysfunctions: definitions and classification. Maturitas 63(2):116–118

    Article  PubMed  Google Scholar 

  30. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB (2008) Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 112(5):970–978

    Article  PubMed  Google Scholar 

  31. Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, Monz BU (2009) Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry 70(12):1698–1706

    Article  PubMed  Google Scholar 

  32. Smith AM, Lyons A, Ferris JA, Richters J, Pitts MK, Shelley JM, Simpson JM, Heywood W, Patrick K (2012) Incidence and persistence/recurrence of women’s sexual difficulties: findings from the Australian longitudinal study of health and relationships. J Sex Marital Ther 38(4):378–393

    Article  PubMed  Google Scholar 

  33. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the Fact-B. Breast Cancer Res Treat 55(2):189–199

    Article  CAS  PubMed  Google Scholar 

  34. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 15(3):974–986

    CAS  PubMed  Google Scholar 

  35. Derogatis L, Clayton A, Lewis-D’Agostino D, Wunderlich G, Fu Y (2008) Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 5(2):357–364

    PubMed  Google Scholar 

  36. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R Jr (2002) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191–208

    Article  Google Scholar 

  37. Derogatis L, Clayton A, Lewis-D’Agostino D, Wunderlich G, Fu Y (2008) Validation of the female sexual distress scale—revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 5(2):357–364

    PubMed  Google Scholar 

  38. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J (2002) The female sexual distress scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 28(4):317–330

    Article  PubMed  Google Scholar 

  39. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression, 2nd edn. Wiley, New York

    Book  Google Scholar 

  40. Mercadante S, Vitrano V, Catania V (2010) Sexual issues in early and late stage cancer: a review. Support Care Cancer 18(6):659–665

    Article  PubMed  Google Scholar 

  41. Gilbert E, Ussher JM, Perz J (2010) Sexuality after breast cancer: a review. Maturitas 66(4):397–407

    Article  PubMed  Google Scholar 

  42. Bradford A (2013) Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause 20(2):128–129

    PubMed  Google Scholar 

  43. Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De Vries J (2010) Clinical factors are not the best predictors of quality of sexual life and sexual functioning in women with early stage breast cancer. Psychooncology 19(6):646–656

    Article  Google Scholar 

  44. Harirchi I, Montazeri A, Zamani Bidokhti F, Mamishi N, Zendehdel K (2012) Sexual function in breast cancer patients: a prospective study from Iran. J Exp Clin Cancer Res 31:20

    Article  PubMed Central  PubMed  Google Scholar 

  45. Pérez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB (2010) Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17(5):924–937

    Article  PubMed Central  PubMed  Google Scholar 

  46. Kingsberg SA (2010) Sexual problems in breast cancer survivors: do not turn good news into no news. Menopause 17(5):894–895

    Article  PubMed  Google Scholar 

  47. Katz A (2005) The sounds of silence: sexuality information for cancer patients. J Clin Oncol 23(1):238–241

    Article  PubMed  Google Scholar 

  48. Park ER, Norris RL, Bober SL (2009) Sexual health communication during cancer care: barriers and recommendations. Cancer J 15(1):74–77

    Article  PubMed  Google Scholar 

  49. Brandenburg U, Bitzer J (2009) The challenge of talking about sex: the importance of patient-physician interaction. Maturitas 63(2):124–127

    Article  PubMed  Google Scholar 

  50. Bober SL, Carter J, Falk S (2013) Addressing female sexual function after cancer by internists and primary care providers. J Sex Med 10(Suppl 1):112–119

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Medicine, Centre de santé et services sociaux de Gatineau, Gatineau, QC, J8P 7H2, Cananda

    Dominique Frechette

  2. Department of Psychology, Carleton University, 1125 Colonel By Dr, Ottawa, ON, K1S 5B6, Canada

    Lise Paquet

  3. Division of Medical Oncology, Department of Medicine, University of Ottawa, The Ottawa Hospital Cancer Centre, Ottawa, ON, K1H 8L6, Canada

    Shailendra Verma, Mark Clemons, Paul Wheatley-Price, Stan Z. Gertler, Xinni Song & Susan Dent

  4. The Ottawa Hospital Cancer Centre, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada

    Nadine Graham

Authors
  1. Dominique Frechette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lise Paquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shailendra Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Wheatley-Price
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stan Z. Gertler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xinni Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nadine Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Susan Dent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan Dent.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frechette, D., Paquet, L., Verma, S. et al. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. Breast Cancer Res Treat 141, 111–117 (2013). https://doi.org/10.1007/s10549-013-2659-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2659-y

Keywords

Search

Navigation